

MGC Pharmaceuticals Limited

MGC has announced the results of a successful clinical study ('the Study') into the influence of its proprietary product, ArtemiC Support®, on patients with Post-Acute COVID Syndrome, also known as Long COVID. These demonstrate the statistically-significant efficacy of ArtemiC Support® in reducing the severity of a range of related symptoms, including Dyspnea, Cough, Asthenia, Headache and Mental Confusion, and represent another step forward in demonstrating the ArtemiC™ range's efficacy in treating patients suffering from both COVID-19 and Long COVID. Considering also the confirmation of 27 June 2022 that its sister product, CimetrA™, which is based on the same four natural ingredients, detailed results from a preclinical *in vitro* study that indicated it has further wide-ranging application as an anti-inflammatory treatment, potentially making it suitable for use in a number of additional common health conditions, their combined treatment opportunity appears to have expanded considerably. Taken together, these announcements represent important steps forward for MGC, not only in terms of building on research that has already been carried out in Israel and India, including CimetrA™'s prospective move into its Phase III clinical trial on route to securing FDA regulatory approval, but also that it is prospectively broadening both access and application for all of its phyto-medicine products across the global market place.

Persistent symptoms of Long COVID

Long-COVID refers to a variety of symptoms affecting different organs reported by people four or more weeks after being infected with SARS-COV-2, the virus responsible for COVID-19. There is presently no approved treatment for the condition and to date, there remains no robust estimates of the incidence and co-occurrence of long-COVID features, their relationship to age, sex, or severity of infection. An [academic paper](#) of 28 September 2021, however, provided a 6-month retrospective cohort study of 273,618 survivors of COVID-19 that concluded that 57.00% had one or more long-COVID feature recorded during the whole 6-month period (i.e., including the acute phase), and 36.55% between 3 and 6 months, typically across nine clinical features.

Given such statistics have been widely recognised by different national health services, such as the UK's NHS which is now offering specialist help at clinics across the country, there is clearly significant and urgent need for an approved range of prescriptive and OTC products suitable for addressing both the needs of hospitalised patients and those that continue to suffer a lower quality of life during their post-infection recovery.

ArtemiC Support® demonstrates ability to reduce severe symptoms

During a 6-week period under the supervision of their doctor, 150 patients were administered ArtemiC Support®. Their progress was then measured against a Post-COVID Functional Scale ('PCFS'), and a 10-point Likert scale, one, two, three and 6 weeks after treatment initiation.

This clinical study, being sponsored by Swiss PharmaCan AG ('SPC') and co-sponsored by MGC Pharma and Glow LifeTech Ltd, was undertaken to obtain partial results on the effectiveness and safety of the product, which has statistically demonstrated the ability of the supplement to improve the symptoms of Long COVID. It was undertaken in conjunction with primary care clinicals in Barcelona, CAP Can Bou and Sardenya EAP on an open label basis, with patients being administered in the form of an oral spray. The symptoms measured include: 1. Dyspnea - shortness of breath; 2. Asthenia - abnormal physical weakness or lack of energy; 3. Anosmia - loss of senses of smell; 4. Ageusia -

Stock Data

Share Price:	1.15p
Market Cap.:	£31.37m
Shares in issue:	2,728m
52 week high/low:	3.95p/0.85p

Company Profile

Sector:	Healthcare
Ticker:	MXC
Exchange:	LSE, ASX

Activities

MGC Pharmaceuticals Limited ('MGC', 'MGC Pharma' 'the Group') is a European-based, vertically integrated bio-pharma company supplying EU-GMP phytomedicine and phytocannabinoid-derived products to patients.

www.mgcpharma.com.au/

Share Price Performance since Admission*



*MGC Pharmaceuticals shares Admitted to the Standard Listing Segment of the Official List on 9 February 2021
Source: [LSE](#)

Past performance is not an indication of future performance.

Turner Pope contact details

Tel: 0203 657 0050
Email: info@turnerpope.com
Web: www.turnerpope.com

Andrew Thacker
Corporate Broking & Sales

Barry Gibb
Research Analyst


TPI acts as sole UK broker to MGC Pharmaceuticals Limited.

Attention is drawn to the disclaimers and risk warnings at the end of this document.

Retail clients (as defined by the rules of the FCA) must not rely on this document.

loss of sense of taste; 5. Cough; 6. Headache and: 7. Mental confusion. Results indicated significant efficacy in reducing the severity of a number of Long COVID symptoms. This follows MGC's 15 December 2020 announcement that ArtemiC™ had completed a Phase II Clinical Trial which demonstrated safety and efficacy in treating patients diagnosed with moderate COVID-19.

The graphs below show the EMMEAN ('Estimated Marginal Mean') observed results from data collected during the Artemic Support® Long COVID study:



Source: MGC, [RNS of 14 July 2022](#)

MGC positioned to fulfil its growth ambitions

MGC continues to pass a number of important milestones. During a very busy past 12 months, it has laid the foundations for the Group's continued growth and future success, which has included progressing both clinical trials and studies and securing entry into the world's largest healthcare market, while also producing its strongest consecutive quarter-on-quarter result in Q3 2021 from sales receipts which in turn allowed it to deliver over AUD\$2.2m of cash inflows. Adding the net proceeds from the £5.5m (gross) capital raising completed on 30 November 2021 which, together with existing cash-in-hand, left it with AUD\$4.0m at end-March 2022. Together with undrawn facilities, this appears to adequately resource the Group to service expected CimetrA™ needs through to its anticipated Emergency Use Authorisation in different jurisdictions, with high-margin scale production through its Maltese facility coming onstream this summer along with continued co-sponsoring of clinical studies for its expanded ArtemiC™ product range. In tandem with this, MGC is expected to further progress CimetrA™'s Phase III clinical trial alongside Phase IIb trials of phytocannabinoid derived CannEpi® (targeting c.50 million people globally who suffer with Epilepsy and specifically the 33% of those with Drug Resistant Epilepsy), and design of the next phase of CogniCann®'s clinical trials which will define appropriate End Points and patient sample size.

Accordingly, the remainder of 2022 looks set to remain an active and exciting period for MGC, as it continues to add value to its portfolio of pharmaceutical products on route to their gaining regulatory approval and/or securing international commercial partnerships/distribution agreements with larger sector players.

THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.

Conflicts

This is a non-independent marketing communication under the rules of the Financial Conduct Authority ("FCA"). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited ("TPI") has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

Risk Warnings

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Any opinions expressed in this document are those of TPI's research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently, AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

Specific disclaimers

TPI acts as sole UK broker to MGC Pharma Limited ('MGC Pharma'). MGC Pharma is dual-listed on the London Stock Exchange's Standard List and the Australian Stock Exchange's ASX. TPI's private and institutional clients may hold, subscribe for or buy or sell MGC Pharma's securities.

Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. TPI has no authority whatsoever to make any representation or warranty on behalf of MGC Pharma.

General disclaimers

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2022 Turner Pope Investments (TPI) Limited, all rights reserved.